{
  "url": "https://openlegislation.uk/eu-regulation-2012-618/annex-II",
  "json_url": "https://openlegislation.uk/eu-regulation-2012-618/annex-II.json",
  "legislation": "eur/2012/618",
  "legislation_title": "Commission Regulation (EU) No 618/2012 of 10 July 2012 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2012-618",
  "path": "annex/II",
  "kind": "annex",
  "number": "II",
  "heading": null,
  "text": "Index No\nInternational Chemical Identification\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits, M-factors\nNotes\nHazard Class and Category Code(s)\nHazard Statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n‘015-199-00-X\ntris[2-chloro-1-chloromethyl)ethyl] phosphate\n237-159-2\n13674-87-8\nCarc. 2\nH351\nGSH08\nWng\nH351\n015-200-00-3\nindium phosphide\n244-959-5\n22398-80-7\nCarc. 1B\nRepr. 2\nSTOT RE 1\nH350\nH361f\nH372 (lungs)\nGHS08\nDgr\nH350\nH361f\nH372 (lungs)\nSTOT RE 1;\nH372: C ≥0,1 %\nCarc 1B;\nH350: C ≥0,01 %\nSTOT RE 2;\nH373: 0,01 % ≤ C < 0,1 %\n015-201-00-9\ntrixylyl phosphate\n246-677-8\n25155-23-1\nRepr. 1B\nH360F\nGHS08\nDgr\nH360F\n015-202-00-4\ntris(nonylphenyl) phosphite\n247-759-6\n26523-78-4\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n015-203-00-X\ndiphenyl(2,4,6-trimethylbenzoyl)phosphine oxide\n278-355-8\n75980-60-8\nRepr. 2\nH361f (causing atrophy of the testes)\nGHS08\nWng\nH361f (causing atrophy of the testes)\n602-109-00-4\nHexabromocyclododecane [1]\n247-148-4 [1]\n25637-99-4[1]\nRepr. 2\nLact.\nH361\nH362\nGHS08\nWng\nH361\nH362\n1,2,5,6,9,10-hexabromocyclododecane [2]\n221-695-9[2]\n3194-55-6[2]\n606-143-00-0\nabamectin (combination of avermectin B1a and avermectin B1b) (ISO) [1]\n_ [1]\n71751-41-2 [1]\nRepr. 2\nAcute Tox. 2\nAcute Tox. 1\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH361d\nH300\nH330\nH372 (nervous system)\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH361d\nH300\nH330\nH372 (nervous system)\nH410\nSTOT RE 1;\nH372: C ≥ 5 %\nSTOT RE 2;\nH373: 0,5 % ≤C<5 %\nM = 10 000\navermectin B1a (purity ≥80 %); [2]\n265-610-3 [2]\n65195-55-3 [2]\n606-144-00-6\nacequinocyl (ISO);\n3-dodecyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate\n—\n57960-19-7\nSkin Sens. 1\nSTOT SE 1\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH370 (lung)\n(inhalation)\nH373 (blood system)\nH400\nH410\nGHS07\nGHS08\nGHS09\nDgr\nH317\nH370 (lung)\n(inhalation)\nH373 (blood system)\nH410\nM = 1 000\n607-698-00-1\n4-tert-butylbenzoic acid\n202-696-3\n98-73-7\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4\nH360F\nH372\nH302\nGHS07\nGHS08\nDgr\nH360F\nH372\nH302\n612-281-00-2\nleucomalachite green;\nN,N,N',N'-tetramethyl-4,4'-benzylidenedianiline\n204-961-9\n129-73-7\nCarc. 2\nMuta. 2\nH351\nH341\nGHS08\nWng\nH351\nH341\n616-205-00-9\nMetazachlor (ISO);\n2-chloro-N-(2,6-dimethylphenyl)-N-(1H-pyrazol-1-ylmethyl)acetamide\n266-583-0\n67129-08-2\nSkin Sens. 1B\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH351\nH400\nH410\nGHS07\nGHS08\nGHS09\nWng\nH317\nH351\nH410\nM = 100\nM = 100’",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2012/618/annex/II",
    "retrieved_at": "2026-11-01T14:49:19.760174+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}